Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms

Human Pathology

Volumn 38, Issue 9, 2007, Pages 1361-1371

  Kenerson, Heidi ^a,b   Folpe, Andrew L ^c   Takayama, Thomas K ^b   Yeung, Raymond S ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

AML; Immunohistochemistry; p70S6K; PEComa; TSC2; Tuberous sclerosis

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; S6 KINASE; TUBERIN;

ANGIOMYOLIPOMA; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; EPITHELIOID CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; VASCULAR TUMOR; WESTERN BLOTTING;

ANGIOMYOLIPOMA; BLOTTING, WESTERN; EPITHELIOID CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; NEOPLASMS, CONNECTIVE AND SOFT TISSUE; ONCOGENE PROTEIN V-AKT; PROTEIN KINASES; PTEN PHOSPHOHYDROLASE; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 34547828815     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.01.028     Document Type: Article

References (46)

1. Folpe A.L. Neoplasms with perivascular epitheloid cell differentiation (PEComas). In: Fletcher C.D.M.U.K., and Mertens F. (Eds). World Health Organization classification of tumors: pathology and genetics of tumors of soft tissue and bone (2002), IARC Press, Lyon 221-222
2. Hornick J.L., and Fletcher C.D. PEComa: what do we know so far?. Histopathology 48 (2006) 75-82
3. Gomez M.R. Definition and criteria for diagnosis. In: Gomez M.R., Sampson J.R., and Whittemore V.H. (Eds). Tuberous sclerosis complex (1999), Oxford University Press, New York 10-23
4. Crino P.B., Nathanson K.L., and Henske E.P. The tuberous sclerosis complex. N Engl J Med 355 (2006) 1345-1356
5. Costello L.C., Hartman T.E., and Ryu J.H. High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc 75 (2000) 591-594
6. Moss J., Avila N.A., Barnes P.M., et al. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med 164 (2001) 669-671
7. Aubry M.C., Myers J.L., Ryu J.H., et al. Pulmonary lymphangioleiomyomatosis in a man. Am J Respir Crit Care Med 162 (2000) 749-752
8. Henske E.P., Neumann H.P., Scheithauer B.W., Herbst E.W., Short M.P., and Kwiatkowski D.J. Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas. Genes Chromosomes Cancer 13 (1995) 295-298
9. Smolarek T.A., Wessner L.L., McCormack F.X., Mylet J.C., Menon A.G., and Henske E.P. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 62 (1998) 810-815
10. Martignoni G., Pea M., Bonetti F., et al. Carcinomalike monotypic epithelioid angiomyolipoma in patients without evidence of tuberous sclerosis: a clinicopathologic and genetic study. Am J Surg Pathol 22 (1998) 663-672
11. Martignoni G., Pea M., Rigaud G., et al. Renal angiomyolipoma with epithelioid sarcomatous transformation and metastases: demonstration of the same genetic defects in the primary and metastatic lesions. Am J Surg Pathol 24 (2000) 889-894
12. Pan C.C., Jong Y.J., Chai C.Y., Huang S.H., and Chen Y.J. Comparative genomic hybridization study of perivascular epithelioid cell tumor: molecular genetic evidence of perivascular epithelioid cell tumor as a distinctive neoplasm. Hum Pathol 37 (2006) 606-612
13. Inoki K., Corradetti M.N., and Guan K.L. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37 (2005) 19-24
14. Wu X., Senechal K., Neshat M.S., Whang Y.E., and Sawyers C.L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 95 (1998) 15587-15591
15. Harris T.E., and Lawrence Jr. J.C. TOR signaling. Sci STKE 2003 (2003) re15
16. Corradetti M.N., Inoki K., Bardeesy N., DePinho R.A., and Guan K.L. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 18 (2004) 1533-1538
17. Johannessen C.M., Reczek E.E., James M.F., Brems H., Legius E., and Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A 102 (2005) 8573-8578
18. Shamji A.F., Nghiem P., and Schreiber S.L. Integration of growth factor and nutrient signaling: implications for cancer biology. Mol Cell 12 (2003) 271-280
19. Manning B.D., Logsdon M.N., Lipovsky A.I., Abbott D., Kwiatkowski D.J., and Cantley L.C. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev 19 (2005) 1773-1778
20. Haruta T., Uno T., Kawahara J., et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol 14 (2000) 783-794
21. Harrington L.S., Findlay G.M., Gray A., et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 166 (2004) 213-223
22. Kenerson H.L., Aicher L.D., True L.D., and Yeung R.S. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 62 (2002) 5645-5650
23. Mak B.C., Kenerson H.L., Aicher L.D., Barnes E.A., and Yeung R.S. Aberrant beta-catenin signaling in tuberous sclerosis. Am J Pathol 167 (2005) 107-116
24. Lizcano J.M., Goransson O., Toth R., et al. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 23 (2004) 833-843
25. Ma L., Chen Z., Erdjument-Bromage H., Tempst P., and Pandolfi P.P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121 (2005) 179-193
26. Folpe A.L., Mentzel T., Lehr H.A., Fisher C., Balzer B.L., and Weiss S.W. Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol 29 (2005) 1558-1575
27. Paradis V., Laurendeau I., Vieillefond A., et al. Clonal analysis of renal sporadic angiomyolipomas. Hum Pathol 29 (1998) 1063-1067
28. Saxena A., Alport E.C., Custead S., and Skinnider L.F. Molecular analysis of clonality of sporadic angiomyolipoma. J Pathol 189 (1999) 79-84
29. Cheng L., Gu J., Eble J.N., et al. Molecular genetic evidence for different clonal origin of components of human renal angiomyolipomas. Am J Surg Pathol 25 (2001) 1231-1236
30. de Jong B., Castedo S.M., Oosterhuis J.W., and Dam A. Trisomy 7 in a case of angiomyolipoma. Cancer Genet Cytogenet 34 (1988) 219-222
31. Dal Cin P., Sciot R., Van Poppel H., Baert L., Van Damme B., and Van den Berghe H. Chromosome analysis in angiomyolipoma. Cancer Genet Cytogenet 99 (1997) 132-134
32. Wullich B., Henn W., Siemer S., Seitz G., Freiler A., and Zang K.D. Clonal chromosome aberrations in three of five sporadic angiomyolipomas of the kidney. Cancer Genet Cytogenet 96 (1997) 42-45
33. van den Berg E., Dijkhuizen T., Storkel S., Molenaar W.M., and de Jong B. Chromosomal abnormalities in non-neoplastic renal tissue. Cancer Genet Cytogenet 85 (1995) 152-154
34. Kattar M.M., Grignon D.J., Eble J.N., et al. Chromosomal analysis of renal angiomyolipoma by comparative genomic hybridization: evidence for clonal origin. Hum Pathol 30 (1999) 295-299
35. El-Hashemite N., Zhang H., Henske E.P., and Kwiatkowski D.J. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet 361 (2003) 1348-1349
36. Robb V.A., Astrinidis A., and Henske E.P. Frequent [corrected] hyperphosphorylation of ribosomal protein S6 [corrected] in lymphangioleiomyomatosis-associated angiomyolipomas. Mod Pathol 19 (2006) 839-846
37. Cheadle J.P., Reeve M.P., Sampson J.R., and Kwiatkowski D.J. Molecular genetic advances in tuberous sclerosis. Hum Genet 107 (2000) 97-114
38. Xu G., Zhang W., Bertram P., Zheng X.F., and McLeod H. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 24 (2004) 893-900
39. Cohen E. mTOR inhibitors. Clin Adv Hematol Oncol 4 (2006) 38-39
40. Webster A.C., Lee V.W., Chapman J.R., and Craig J.C. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 81 (2006) 1234-1248
41. Kenerson H., Dundon T.A., and Yeung R.S. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res 57 (2005) 67-75
42. Lee L., Sudentas P., Donohue B., et al. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer 42 (2005) 213-227
43. Pantuck A.J., Thomas G., Belldegrun A.S., and Figlin R.A. Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications. Semin Oncol 33 (2006) 607-613
44. Recher C., Dos Santos C., Demur C., and Payrastre B. mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle 4 (2005) 1540-1549
45. Karbowniczek M., and Henske E.P. The role of tuberin in cellular differentiation: are B-Raf and MAPK involved?. Ann N Y Acad Sci 1059 (2005) 168-173
46. Mak B.C., Takemaru K., Kenerson H.L., Moon R.T., and Yeung R.S. The tuberin-hamartin complex negatively regulates beta-catenin signaling activity. J Biol Chem 278 (2003) 5947-5951